Ligand Pharmaceuticals Incorporated (LGND)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 830,439 | 700,913 | 597,485 | 821,629 | 709,525 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $830,439K)
= 0.00
Based on the provided data, Ligand Pharmaceuticals Incorporated has consistently maintained a debt-to-capital ratio of 0.00 over the five-year period from December 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt to finance its operations or investments relative to its total capital. A debt-to-capital ratio of 0.00 typically suggests that the company is financing its activities primarily through equity or internal funds, resulting in lower financial risk as there is no debt repayment obligation. However, it is important to note that while a low debt-to-capital ratio may reflect a strong financial position in terms of solvency and stability, it could also imply potentially missed opportunities for leveraging debt to potentially enhance returns on equity.
Peer comparison
Dec 31, 2024